Objective To study the value of serum tartrate-resistant acid phosphatase 5b (TRACP5b) in bone metastasis in early breast cancer patients with negative axillary lymph nodes.Methods The serum level of TRACP5b was determined by enzyme-linked immumosorbent assay (ELISA) in 26 breast cancer patients and 18 healthy female adults.Results The serum level of TRACP5b was (3.85 ± 0.85) U/L in the group of breast cancer patients and (2.08 ± 0.84) U/L in the control group.The difference had statistical significance (P ＜0.05 ).The sensitivity was 42.31％ and the specificity was 94.44％ for TRACP5 b in predicting bone metastasis of breast cancer with negtive axillary lymph nodes.Conclusions TRACP5b has higher sensitivity and specificity in breast cancer patients than in healthy female adults.TRACP5b is a useful serum marker to predict bone metastasis in breast cancer patients.

Objective To explore the association between test results of human biological stimulation feedback instrument (EZSCAN) and blood glucose levels. Methods Data were collected from the general population who received health checkups that included examination of the autonomic nervous system function using the EZSCAN human biological stimulation feedback instrument from January to December 2017 in Shanghai Eastern Hospital. In accordance with the inclusion and exclusion criteria, 2136 cases (1122 men and 1024 women), with an average age of (50.7 ± 12.9) years, were enrolled in the final analysis. Participants were divided according to the diabetic risk scores obtained by EZSCAN into the control group (n=784 cases), low-risk group (n=801 cases), and high-risk group (n=551 cases). Fasting plasma glucose (FPG) and glycosylated hemoglobin (HbA1c) levels were statistically compared between groups. Participants were divided into four groups according to FPG quartiles [Group F1 (FPG≤4.76 mmol/L, n=546 cases), Group F2 (4.76 mmol/L5.58 mmol/L, n=528 cases)] and HbA1c quartiles [Group H1 (HbA1c≤5.3％, n=630 cases), Group H2 (5.3％5.9％, n=457 cases)]. EZSCAN test results were compared between the quartile groups. Correlations between EZSCAN results and FPG levels and HbA1C levels were analyzed. Results There were statistical differences in both FPG levels and HbA1c levels between participants in the control group, low-risk group, and high-risk group [FPG: (5.10 ± 1.06) mmol/L, (5.47 ± 1.36) mmol/L, and (5.59 ± 1.32) mmol/L, respectively, F=29.47, P<0.05; HbA1C:(5.95 ± 0.99)％, (5.79 ± 0.89)％, and (5.50 ± 0.70)％, respectively, F=47.42, P<0.05]. With increases in both FPG and HbA1C quartile levels, the EZSCAN scores showed a statistically increasing tendency [Groups F1-F4:(30.1 ± 14.6), (32.9 ± 15.2), (33.8 ± 15.1), and (39.1 ± 15.6), F=32.98, P<0.05;Groups H1-H4: (29.1 ± 14.4), (31.9 ± 14.2), (37.2 ± 15.3), and (40.3 ± 15.8), F=61.36, P<0.05]. Both FPG and HbA1c levels were positively correlated with diabetic risk scores (r=0.22 and 0.32, P<0.05). Conclusion Test results using the EZSCAN human biological stimulation feedback instrument showed significantly positive correlations with blood glucose levels.